

CURRICULUM VITAE

Robert Dale (Bob) Langer, M.D., M.P.H.

Titles:

Principal Scientist and Medical Director
Jackson Hole Center for Preventive Medicine, Jackson, Wyoming

Clinical Professor of Family Medicine, University of Nevada, Reno School of Medicine

Office Phone:

(213) 537-4397 or (307) 223-7374

Cell Phone:

(619) 993-4360

Office Address: Jackson Hole Center for Preventive Medicine
577 Royal Loop
Etna, WY 83118

Email:

rdlanger@jhcpm.com

HIGHER EDUCATION:

College	Tufts College Medford, Massachusetts Bachelor of Arts (English), <i>cum laude</i> - 1972
Medical School:	University of Illinois at the Medical Center, Chicago Abraham Lincoln School of Medicine Doctor of Medicine, <i>James Scholar</i> – 1978
Graduate School in Public Health:	San Diego State University, Graduate School of Public Health, Masters in Public Health with specialization in Epidemiology – 1988

POST-DOCTORAL TRAINING:

Residency in Family Medicine: Overlook Family Practice Program, Overlook Hospital - a teaching affiliate of Columbia College of Physicians and Surgeons, (one year), Summit, New Jersey, 1978 – 1979

Residency in Preventive Medicine: University of California - San Diego State University, General Preventive Medicine Program, San Diego, California, 1986 – 1988

BOARD CERTIFICATION, LICENSURE and FELLOWSHIPS:

Medical License: California Physician and Surgeon Certificate (since 1979)

Pennsylvania Medical Physician and Surgeon Certificate (since 2005)

Wyoming Physician/Surgeon Certificate (since 2007)

Colorado Physician and Surgeon Certificate (since 2010)

Board Certification: Diplomat of the American Board of Preventive Medicine, 1992

Fellowships: American Academy of Family Physicians (1988)

American Heart Association Council on Epidemiology and Prevention (1991)

American College of Preventive Medicine (1993)

PROFESSIONAL EXPERIENCE:

- Aug 1979* – Staff Physician at (*concurrent part-time positions*):
- Feb 1980:*
- Chicano Community Clinic, 1809 National Avenue, San Diego, California
 - East County Community Clinic, 205 Prescott, El Cajon, California
 - Kaiser Permanente Medical Group, Department of Family Practice, Urgent Appointments Clinic, Zion Hospital, San Diego, California
- Feb 1980* – Physician and Managing Partner, The Center For Health Medical Group, a prevention-oriented family practice, San Diego, California
- June 1986:*
- Jul 1986* – Resident in General Preventive Medicine, University of California, San Diego and graduate student in Public Health, San Diego State University
- June 1988:*
- Jul 1988* – Assistant to Associate Professor, Department of Family and Preventive Medicine, Division of Epidemiology, University of California, San Diego, School of Medicine, La Jolla, California
- June 2000:*
- Jun 2000* – Professor of Family and Preventive Medicine, University of California, San Diego, La Jolla, California
- Sept 2005:*
- Sept 2005* – Director, Outcomes Research Institute, Geisinger Health System, Danville, Pennsylvania
- Dec 2008*
- Mar 2006* – Adjunct Professor of Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, Pennsylvania
- Dec 2008*
- Nov 2008-present* – Principal Scientist and Medical Director, Jackson Hole Center for Preventive Medicine, Epidemiology and Preventive Medicine, Jackson, Wyoming
- Jun 2009-Jun 2012* – Adjunct Scholar in Epidemiology, University of Pennsylvania Center for Clinical Epidemiology and Biostatistics
- Jan 2010-Jun 2012* – Adjunct Professor, University of Nevada School of Medicine, Department of Family Medicine – Las Vegas
- Jun 2012-April 2017* – Professor of Family Medicine – Las Vegas, University of Nevada School of Medicine
- Aug 2012-2016* – Research Professor, University of Nevada, Las Vegas, School of Allied Health Sciences
- Dec 2012-2017* – Associate Dean for Clinical and Translational Research, University of Nevada, Reno School of Medicine
- Apr 2017-present* – Clinical Professor of Family Medicine, University of Nevada, Reno School of Medicine

RESEARCH:

As Principal Investigator (from most recent), # left at UNLV, ^left at Geisinger, * left at UCSD

- 2017- HRT Use and Incident Major Diseases in the Wake of the WHI. Office of the Nevada Attorney General Womens Health Initiative Funds.
- 2013- Mountain West Clinical Translational Research – Infrastructure Network (CTR-IN). National
2018# Institute of General Medical Sciences – NIH. A comprehensive program to accelerate the development of capacity, and the necessary institutional culture change, to advance clinical and translational research in 7 western IDeA States (AK, ID, HI, MT, NM, NV, WY) to the benefit of our culturally diverse, diffuse and often remote, underserved populations. The CTR-IN serves a consortium of 13 universities distributed across a sparsely populated region that represents 1/3 of the US landmass. (PI)
- 2008- An Algorithm to Improve Performance on a Quality Measure for Acute Bronchitis. National
2011^ Center for Infectious Diseases, Centers for Disease Control. A cluster-randomized clinical trial to assess the effect of an algorithm to reduce inappropriate prescription of antibiotics in acute bronchitis in outpatient clinics. Conducted in collaboration with the University of Pennsylvania and the University of California, San Francisco. (Site PI)
- 2007- Community-Based Control and Persistence of Warfarin Therapy and Associated Rates and
2010^ Predictors of Adverse Clinical Events in Atrial Fibrillation and Venous Thromboembolic Disease. National Heart, Lung and Blood Institute. A collaborative retrospective study conducted within the Cardiovascular Research Network using electronic health records. (Site PI)
- 2007 – Cardiovascular Research Network. National Heart, Lung and Blood Institute. A national
2012^ collaborative research group focused on cardiovascular research using patient populations from 7 member institutions of the HMO Research network (Site PI).
- 2007 – Cancer Research Network. National Cancer Institute. A national collaborative research group
2012^ focused on cancer research using patient populations from 7 member institutions of the HMO Research network (Site PI).
- 2007 – Distributed Research Network. Agency for Healthcare Research and Quality. Design, develop
2009 and implement a scalable distributed research network linking multiple large integrated U.S. health systems (Site PI).
- 2007 – Predictors of Endometriosis in an Integrated Health System. GlaxoSmithKline. Evaluation of risk
2008 factors for incident endometriosis in patients cared for by a large integrated health system. (PI)
- 2006 – Optimal Second Line Therapy for Hypertension. Agency for Healthcare Research and

- 2010 Quality. Analysis of the Geisinger Clinic population longitudinal clinical dataset to assess the patterns of antihypertensive medication use and outcomes associated with different treatments initiated after failure on monotherapy. (PI)
- 2006 – Predictors of Physician and Patient Compliance with Antihypertensive and Lipid
- 2008 Treatment. Pfizer, Inc. Collaborative analysis of primary care populations from the Geisinger Clinic and the University of Pennsylvania to assess the patterns of antihypertensive and lipid-lowering medication use and evaluate the predictors of appropriate initiation and maintenance of treatment. (Site PI)
- 2006 – Newer Sedative-Hypnotics and Cancer. Scripps Clinic Foundation and Dr. Daniel
- 2007 Kripke. Secondary analyses using the Geisinger Clinic population longitudinal dataset to determine if there is an association between use of new sedative/hypnotic drugs and incident cancer or death. (PI)
- 2006 – Adjuvant Chemotherapy for Stage III Colorectal Cancer – Compliance and Outcomes. American
- 2008 Cancer Society. Analyses linking the tumor registry and the longitudinal clinical dataset for the Geisinger Clinic population to assess demographic and medical factors influencing compliance with adjuvant chemotherapy for stage III colorectal cancer, and outcomes according to treatment compliance. (PI)
- 2006 – Patterns of Medication Use for Chronic Pain. Ortho-McNeil, Inc. Analyses of the Geisinger
- 2007 Clinic population longitudinal clinical dataset to determine the patterns of use of medications for chronic pain by patient demographics, by associated diagnoses and by comorbidities. (PI)
- 2005 – MAP.3/ExCel. A phase III randomized study of exemestane versus placebo in postmenopausal
- 2011* women at increased risk of developing breast cancer. National Cancer Institute of Canada. A clinical trial evaluating exemestane, an aromatase inhibitor, for the primary prevention of breast cancer in postmenopausal women at high risk of developing the disease (Site PI).
- 2005 – Prevention of Lung Function Decline with Vitamin E and Selenium (Respiratory Ancillary
- 2013* Study), Southwest Oncology Group/NIH. An ancillary clinical trial to SELECT evaluating the effects of Vitamin E and or Selenium on the progression of chronic obstructive lung disease in men at elevated risk for this condition (Site PI).
- 2005 – Normative Aging Study (a substudy of PREADVISE). Southwest Oncology Group/National
- 2013* Institute of Aging. An ancillary prospective follow-up study nested within SELECT evaluating cognitive function over time in men aged 62 and older (60 and older for African American or Hispanic) (Site PI).
- 2003 – Phase 3 multi-center, double-blind, randomized, parallel group, carotid B-mode ultrasound
- 2006* evaluation of the anti-atherosclerotic efficacy, safety, and tolerability of fixed combination CP-529,414/atorvastatin, administered orally, once daily (QD) for 24 months, compared with atorvastatin alone, in subjects with mixed hyperlipidemia. Pfizer, Inc. A clinical trial evaluating

- the efficacy of an approved statin drug combined with an experimental drug that works in a different way for improving cholesterol levels in subjects with mixed hyperlipidemia (Site PI).
- 2004 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin 2008* (Crestor®) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein (JUPITER). AstraZeneca Pharmaceuticals Inc. A clinical trial evaluating the efficacy of a newly approved statin for reduction of C-Reactive Protein (CRP) subjects with normal LDL and high levels of CRP (Site PI).
- 2004 – Prevention of Alzheimer’s Disease with Vitamin E and Selenium (PREADVISE). Southwest 2013* Oncology Group/National Institute of Aging. An ancillary clinical trial to SELECT evaluating the potential for Vitamin E and or Selenium to prevent cognitive decline or dementia in men aged 62 and older (60 and older for African American or Hispanic) (Site PI).
- 2002 – Fracture incidence reduction and safety of TSE-424 (bazedoxifene acetate) compared to placebo 2004 and raloxifene in osteoporotic postmenopausal women. Wyeth Ayerst Pharmaceuticals. A clinical trial evaluating the efficacy of an experimental drug in comparison to raloxifene and placebo in reducing the incidence of new vertebral fractures in osteoporotic postmenopausal women (Site PI).
- 2001 – Selenium and Vitamin E Cancer Prevention Trial (SELECT). Southwest Oncology 2013* Group/National Cancer Institute. A clinical trial testing selenium and/or vitamin E to reduce the incidence of primary prostate cancer in men aged >55 years (>50 for African American or Hispanic) (Site PI, competitively enrolled largest number of participants among >400 sites, member of the National Steering Committee).
- 2002- Longevity Consortium. National Institute on Aging. A consortium of scientists, from those who 2012 study very simple biologic systems with replication times measured in hours, through those who study long-lived human populations, brought together to collaborate, inform one another, and quickly test findings across disciplines. The goal is to find mechanisms related to aging that may lead to interventions to improve human longevity (Site PI).
- 1993 – Vanguard Clinical Centers For The Women’s Health Initiative (WHI). National Heart, Lung and 2005 Blood Institute - NIH. A clinical trial and observational study of cardiovascular disease, breast and colorectal cancers and osteoporosis in 160,000 postmenopausal women nationwide. 5600 women are enrolled at the UCSD center (Site PI of the 3rd largest of 40 sites, Chair of the National Investigators Committee, Chair of the National Observational Study Committee).
- 1996 – The Effects of Hormone Therapy on the Development and Progression of Dementia: The 2005 Women’s Health Initiative Memory Study. Wake Forest University/Wyeth-Ayerst. A study evaluating the effects of estrogen on memory and cognitive function in older women (Site PI).
- 2002 – Fat Reduction, HRT Use and Benign Breast Disease. Albert Einstein College of

- 2005 Medicine/NIH. A WHI Ancillary study. Examines the effect of dietary fat reduction and hormone replacement therapy on the development and course of benign breast disease and the subsequent development of breast cancer (Site PI).
- 2001 – Protocol Capss-153: A Multicenter, Randomized, Open-Label, Parallel Group Study To Evaluate
2002 The Endometrial Safety Following Treatment With Ortho-Prefest[®] Compared To Prempro[™] In Postmenopausal Women. Ortho-McNeil Pharmaceutical (Site PI). A study comparing two hormone replacement therapies already approved by the FDA for their effect on endometrial safety.
- 1999 - Thrombotic, Inflammatory and Genetic Markers for CHD in Postmenopausal Women
- 2003 Harvard University/NIH-NHLBI. A comprehensive evaluation of a series of thrombotic, inflammatory, and genetic markers for myocardial infarction among participants in the Women's Health Initiative Observational Study (WHI-OS), an ongoing prospective cohort study of over 90,000 ethnically representative post-menopausal American women (Site PI).
- 1998 A Comparison of Continuous HRT Regimens including Estratab[®] combined with Prometrium[®] or
– Provera[®]. Solvay Pharmaceuticals, Inc. A randomized double-blind crossover comparison of two
2000 continuous HRT regimens on the quality of life in post-menopausal women (Site PI).
- 1998 HRT and Quality of Life. Solvay Pharmaceuticals, Inc. Analysis of data contrasting treatment effects of the HRT regimens on Quality of Life over time in the Postmenopausal Estrogen-Progestin Interventions Trial (Site PI).
- 1997 The Effect of Tibolone on Carotid Artery Thickness and Bone Mineral Density (OPAL
– 02 Study). Organon, Inc. A randomized controlled double blinded clinical trial evaluating the effects of a manufactured estrogen, tibolone, compared to CEE+MPA on risk factors for cardiovascular disease and osteoporosis (Site PI).
- 1995 Women's Healthy Eating and Lifestyle Study. Walton Family Foundation
– 96 A clinical trial of secondary prevention of breast cancer by diet (Site PI).
- 1995 Partners in Women's Health Study. Stein Institute for Research on Aging. An observational study
– 96 of prostate and cardiovascular disease in male partners of women enrolled in the WHI (PI).
- 1991 Predictors of Cardiovascular Disease in the Elderly. NIH:NHLBI. An observational study of risk
– 95 factors associated with disease in persons aged 75 and older (PI).

As Co-Principal Investigator (beginning with most recent)

- 2006 Molecular Biomarkers for Abdominal Aortic Aneurysms. Geisinger Clinic Research
– Endowment. A case-control study conducted in patients followed for abdominal aortic aneurysm
2007 (AAA) and controls with other peripheral arterial disease, built upon suggestive findings in lower
mammals, to identify potential genetic markers associated with AAA.
- 1995 The Epidemiology of Venous Disease. NIH:NHLBI. An observational study of the prevalence and
– 99 predictors of venous vascular disease in adult male and female volunteers. Co-Principal
Investigator. Principal Investigator: Michael H. Criqui, MD, MPH
- 1994 PEPI: Postmenopausal Estrogen-Progestin Interventions Trial II. NIH:NHLBI. Support for
– 98 scientific follow-up activities for the completed multi-center PEPI trial that studied the associations
between hormone replacement therapy and cardiovascular disease risk factors. Co-Principal
Investigator and member of the Publications and Ancillary Studies Committee. Principal
Investigator: Dr. Elizabeth Barrett-Connor.
- 1994 PEPI: Postmenopausal Estrogen-Progestin Interventions Trial Safety Follow-
– 97 up. NIH:NHLBI. Support for clinical safety follow-up activities for the completed multi-center
PEPI trial that studied the associations between hormone replacement therapy and cardiovascular
disease risk factors. Co-Principal investigator, Project Director, and Clinic Physician for the UCSD
Clinical Center. Principal Investigator: Dr. Elizabeth Barrett-Connor.
- 1987 PEPI: Postmenopausal Estrogen-Progestin Interventions Trial. NIH:NHLBI. A multi-center PEPI
– trial that studied the associations between hormone replacement therapy and cardiovascular disease
1994 risk factors. Co-Principal investigator, Project Director, and Clinic Physician for the UCSD
Clinical Center. Principal Investigator: Dr. Elizabeth Barrett-Connor.
- 1991 The Natural History of Peripheral Arterial Disease (PAD). NIH: NHLBI. A study using repeat
– 95 non-invasive tests for PAD on a population of veterans identified as having this condition. Co-
Principal Investigator. Principal Investigator: Michael H. Criqui, MD, MPH
- 1986 The Epidemiology of Peripheral Arterial Disease (PAD). NIH: NHLBI. An observational study of
– 91 the prevalence of PAD and the prospective outcomes associated with categories of PAD in older
men and women. Co-Principal Investigator. Principal Investigator: Michael H. Criqui, MD, MPH

As Co-Investigator

- 2008- The Built Environment and Cancer in Women's Health Initiative participants in San Diego.
- 2010 NIH: National Cancer Institute. A study investigating associations between the neighborhood environment, cancer risk factors and outcomes. Co-Investigator. Principal Investigator: Matthew Allison, MD, MPH
- 2008- Bridging Knowledge Gaps in the Comparative Effectiveness of ACE Inhibitors and
2010 ARBs. Agency for Healthcare Research and Quality. A retrospective study using electronic medical records to assess outcomes associated with use of these two newer antihypertensive agents. Co-Investigator. Principal Investigator: Nirav Shah, MD, MPH
- 2001 – Cardiac Amyloidosis in Aging African-Americans. NIH: NHLBI. A study examining a
2004 genetically determined form of late-onset amyloidosis due to a substitution of ILE for VAL on position 122 in the serum protein transthyretin (TTR). Co-Investigator. Principal Investigator: Joel Buxbaum, MD
- 1986 – Rancho Bernardo Chronic Disease Study: Diabetes and Macrovascular Disease in an Adult
2002 Community. NIH:NIDDK. A community-based study of the association between macrovascular disease, diabetes, other major chronic diseases and associated risk factors in a cohort of men and women followed prospectively in Rancho Bernardo, California, since 1972. Co-Investigator with focus on the very old, blood pressure and electrocardiography. Principal Investigator: Elizabeth Barrett-Connor, MD
- 1995 Ethnic Differences in Bone Mineral Density in Postmenopausal Women
– 96 Stein Institute for Research on Aging. An observational study comparing bone mineral density in Latina, Anglo and African-American women. Co-Investigator with responsibility for coordinating data collection activities between the WHI project and the other UCSD units involved, role in the design and conduct of analyses. Principal Investigator: Diane Schneider, MD
- 1986 Preventive Cardiology Academic Award. NIH:NHLBI. *Preventive Cardiology Center*. An
– educational and behavior change program involving physicians-in-training and patients at
2005 increased cardiovascular risk. Physician and Co-Investigator. Data base design, analyses and manuscript preparation. *Medical Student Risk Assessment*. Associate Director, and Acting Director, 1991-92. Data base design, analyses and manuscript preparation. Principal Investigator: Michael H. Criqui, MD, MPH
- 1995 Validation and Exploration of Sleep and Mood Predictors. NIH:NHLBI. An observational study
– 99 conducted in the San Diego Women's Health Initiative cohort of the associations between sleep, chronic diseases and survival, and a validation study of the WHI sleep questionnaire. Co-Investigator with responsibility for coordinating enrollment, data collection and analysis activities between the main WHI project and Dr. Kripke's lab. Principal Investigator: Daniel Kripke, PhD

RESPONSIBILITIES AT THE UNIVERSITY OF NEVADA SCHOOL OF MEDICINE:***Associate Dean for the Office of Medical Research in Las Vegas:***

Planning and design of physical plant to house research support staff and clinical exam space

Definition and hiring of staff positions to support clinical and translational research for the main clinical campus of the medical school

Development of research capacity at the primary clinical campus

Mentor/Advisor for junior and mid-career faculty developing clinical research (3-5 per year)

Member, Conflict of Interest Committee

Faculty for Annual Research Boot Camp

RESPONSIBILITIES AT THE GEISINGER HEALTH SYSTEM:***Founding Director of the Outcomes Research Institute***

Electronic Health Record:

Development of a core dataset representing the main characteristics and outcomes for the population of approximately 1.2 million patients with longitudinal records served by the system

Mentor/Advisor for (typically 3 to 5 per year):

Residents in Internal Medicine

Fellows in Cardiology and Women's Health

Junior faculty

Clinical faculty interested in developing/conducting research

Committees and Administration:

Administrative Committee for Research

Senior Research Leadership

RESPONSIBILITIES AT THE UCSD SCHOOL OF MEDICINE:

Professor of Family and Preventive Medicine

Lecturer in:

Core Epidemiology Course

Advanced Epidemiology elective

Clinical Trials elective

Preventive Medicine Elective

Preventive Cardiology Elective

Graduate Seminar in Epidemiology

Mentor/Advisor for (typically 3 to 5 per year):

Thesis and independent study (medical students)

Ph.D. students in the Epidemiology program

MD/PhD students in the Medical Scientist Training Program

Residents in Preventive Medicine

Fellows in Preventive Medicine and Women's Health

Host/advisor for visiting scholars in epidemiology

Clinical:

Family physician for patients followed through the UCSD Medical Group

Committees and Administration:

Department of Family and Preventive Medicine Finance Committee 1999-2004.

Department of Family and Preventive Medicine Executive Committee 1989-93.

Department of Family and Preventive Medicine Committee on Academic Promotions, Chairman 1990-91, member 1989-91.

School of Medicine

Research Working Group, Task Force for LCME self-study, 2002

Academic Geriatric Resource Center of UCSD, Internal Advisory Board, 1991-2005

Search Committee for Family Medicine Division Chief, 2000

Stein Institute for Research on Aging, Internal Advisory Board, 1991-2005

Computer Advisory Committee, 1990-1996

Dean's Ad Hoc Committee for a research institute at the University of Costa Rica, 1990-91.

Core Curriculum Committee, 1992-1994

Task Force on a Curriculum in Medical Informatics, 1994-95

Campus-Wide

Committee on Computing, 1993-97

NATIONAL AND REGIONAL COMMITTEES:

Steering Committee, National IDeA Symposium on Biomedical Research (NISBRE), 2016

Chair, NIGMS IDeA Clinical Translational Research Principal Investigators Committee, 2014 - 2016

Research Committee, American Heart Association, Pennsylvania – Delaware Affiliate, 2006 - 2008

Practice-Based Research Network Committee, Pennsylvania Academy of Family Physicians, 2006 - 2008

Chair, Observational Study Committee, The Women's Health Initiative, 1996-2005

Associate Editor, Sexuality and Reproductive Medicine, 2004 – 2008

Associate Editor, Clinical Journal of Women's Health, 2001 – 2004

Behavioral Science, Epidemiology and Prevention Committee, Consortia Peer Review, American Heart Association, 2000 - 2002

Chair, National Steering Committee, The Women's Health Initiative, 1995-96

National Steering Committee, The Women's Health Initiative, 1994-2005

Chair, National Principal Investigators Committee, The Women's Health Initiative, 1995-96;
Vice-Chair, 1994-95

Chair, Western Region Principal Investigators, The Women's Health Initiative, 1994-96

Chair, American Heart Association Council on Epidemiology and Prevention, Membership and Credentials Committee, 1991-95

Chair, Soroptimist International of La Jolla/Doris A. Howell Foundation for Women's Health Research Student Research Award in Women's Health Scientific Advisory Board, 1994-1998

Task Force on Women's Issues, American Heart Association, Council on Epidemiology and Prevention, 1994-97

National Management Committee, The Women's Health Initiative, 1994-95

Executive Committee, American Heart Association Council on Epidemiology and Prevention, 1991-1995

Postmenopausal Estrogen/Progestins Interventions (PEPI) trial, Publications & Ancillary Studies Committee, 1988 - 1999

Consulting Epidemiologist, American Lung Association San Diego, Committee on Tuberculosis, 1989-94

Member, Membership and Credentials Committee, AHA Council on Epidemiology and Prevention, 1989-1991

Member, Expert Panel, American Academy of Family Physicians, Ad Hoc Panel on Computers; 1983, 1991

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

American Academy of Family Physicians, 1980 - present

Wyoming Academy of Family Physicians, 2007 – present

California and San Diego Academies of Family Physicians, 1982 - 2005

American Society for Preventive Cardiology, 2002 - present

American Heart Association, Council on Epidemiology, 1987- present

American College of Preventive Medicine, 1993 - present

Attending Medical Staff, Geisinger Health System, Danville, PA, 2005 - 2007

Attending Medical Staff, University Hospitals, University of California, San Diego, 1988 - 2005

Attending Medical Staff, Pomerado Hospital, Poway, California, 1981 - 1994

HONORS, AWARDS & FELLOWSHIPS:

Fellow, American Academy of Family Physicians - 1988

Fellow, American Heart Association Seminar on Cardiovascular Epidemiology - 1988

Member, Sam and Rose Stein Institute for Research on Aging, University of California, 1991-2005

Fellow, Council on Epidemiology of the American Heart Association, 1991

Fellow, American College of Preventive Medicine, 1993

Member, UCSD Cancer Center, 1994 - 2005

Annual Robert Langer scholarship for a UCSD undergraduate interested in women's health given by Howell Foundation starting in 2003

INTERNATIONAL INVITED LECTURESHIPS:

Scandinavian Primary Care Symposium, Gothenberg, Sweden, September 2006, “Contrasts in Outpatient Records-Based Research Between US and Swedish Integrated Healthcare Systems”.

Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden, April 2007, “Contemporary Pharmacoepidemiology In a Large Integrated US Health System”.

Skaraborg Regional Health System, Skovde, Sweden, April 2007, “Stark Contrasts in the Control of Blood Sugar & Blood Pressure Among Diabetics In Swedish and US Cohorts”.

Israel Menopause Society, Tel Aviv, Israel, August 2009, “The WHI Findings for HRT Started Near Menopause”.

State of Israel Ministry of Health, National Council For Women's Health, Tel Aviv, Israel, August 2009, “Benefits and Risks for Hormone Replacement Therapy Initiated Near Menopause”.

The Amsterdam Menopause and Women’s Health Symposium. Amsterdam, the Netherlands, September 2010. “The Women’s Health Initiative in Light of Recent Evidence: Time is of the Essence”.

Controversies in Obstetrics, Gynecology and Infertility, Sanya, Hainan, China, December 2011, 3 lectures: “Is There Evidence for a Hormone Therapy Critical Window to Prevent Disease?” “Should we Treat Women with Low Bone Mineral Density Who are Younger than 70 Years, and How?” “It is Impossible to Predict Women in Whom Hormone Therapy Will Increase Breast Cancer Risk and Evidence Is Inadequate to Attribute Risk to Specific Regimens”

American Heart Association Conference on Epidemiology and Prevention, San Diego, CA, March 2012. “Short-acting Hypnotic Drugs Increase Mortality and Obese Patients are Particularly Vulnerable.”

COGI – Building Consensus in Gynecology, Infertility and Perinatology, Barcelona, Spain, May 2012. “Strengths and weaknesses of WHI - methodological perspectives.”

International Menopause Society, Paris, France, November 2012. “HRT: State of the art 10 years after WHI”.

17th Controversies in Obstetrics, Gynecology and Infertility, Lisbon, Portugal. November 2012, 2 lectures: “HRT: Where Do We Come From? Where Are We Going?” “Debate: Is there evidence for a critical HRT window to prevent disease? Proposition: HRT should be started early to have an effect”

18th Controversies in Obstetrics, Gynecology and Infertility, Vienna, Austria. October 2013: “The WHI: Where the Right Went Wrong”

19th Controversies in Obstetrics, Gynecology and Infertility, Macao, China. February 2014, 3 lectures: “Is There A Critical Window for Initiating Hormone Therapy to Prevent Disease?” “The WHI: Where the Right Went Wrong” “Calcium and Vitamin D: Prevention or Harm?”

20th Controversies in Obstetrics, Gynecology and Infertility, Paris, France. December 2014: “Hormone Therapy and Osteoporosis”

21st Controversies in Obstetrics, Gynecology and Infertility, Guilin, China. May 2015, 3 lectures: “The WHI and Breast Cancer” “The WHI: Where the Right Went Wrong” “The WHI and Osteoporosis”

23rd Controversies in Obstetrics, Gynecology and Infertility, Melbourne, Australia. April 2016, 2 lectures: “The WHI: Have We Reached the Wrong Conclusions?”; “The WHI and Osteoporosis”

15th Biennial Congress of the International Menopause Society, Prague, Czech Republic, September 2016, Plenary Lecture: “The Evidence Base for Hormone Replacement Therapy: What Can We Believe?”

24th Controversies in Obstetrics, Gynecology and Infertility, Amsterdam, The Netherlands. November 2016, 2 lectures: “Debate: HRT with proper timing and chosen regimen – Pro side: HRT is cardiovascular protective”; “HRT and Osteoporosis Prevention: Are we under-using the best treatment option?”

6th Scientific Meeting of the Asia Pacific Menopause Federation, Singapore, April 2017. Invited Seminar, “The Subtle Art of Menopause Treatment: Right Women, Right Time”

Indian Menopause Society: Chennai, Mumbai, Kolkata and Delhi, April 2017. “The Evidence Base for HRT: What Can We Believe?”

73rd Annual Clinical and Scientific Conference, Society of Obstetricians and Gynecologists of Canada, Ottawa, Ontario, Canada, June 2017. Invited Plenary, “HRT 15 Years After the First Report from the WHI”.

27th Annual Conference of the British Menopause Society, Chesford Grange, Warwickshire, UK, July 2017. Invited Keynote Lecture, “Reassessing the Women’s Health Initiative.”

German Menopause Society Annual Scientific Conference, Frankfurt, Germany, November 2017. Invited Keynote, “The WHI Revisited: Old Story, New Insights.”

Royal College of Obstetricians and Gynaecologists, 2017 Professional Development Conference, London, UK, November 2017. Invited Keynote, “Re-assessing the WHI HRT Trials: What Happened? What Can We Believe?”

24th Controversies in Obstetrics, Gynecology and Infertility, Amsterdam, The Netherlands. November 2016, 2 lectures: “Debate: HRT with proper timing and chosen regimen – Pro side: HRT is cardiovascular protective”; “HRT and Osteoporosis Prevention: Are we under-using the best treatment option?”

6th Scientific Meeting of the Asia Pacific Menopause Federation, Singapore, April 2017. Invited Seminar, “The Subtle Art of Menopause Treatment: Right Women, Right Time”

Indian Menopause Society: Chennai, Mumbai, Kolkata and Delhi, April 2017. “The Evidence Base for HRT: What Can We Believe?”

73rd Annual Clinical and Scientific Conference, Society of Obstetricians and Gynecologists of Canada, Ottawa, Ontario, Canada, June 2017. Invited Plenary, “HRT 15 Years After the First Report from the WHI”.

27th Annual Conference of the British Menopause Society, Chesford Grange, Warwickshire, UK, July 2017. Invited Keynote Lecture, “Reassessing the Women’s Health Initiative.”

German Menopause Society Annual Scientific Conference, Frankfurt, Germany, November 2017. Invited Keynote, “The WHI Revisited: Old Story, New Insights.”

Royal College of Obstetricians and Gynaecologists, 2017 Professional Development Conference, London, UK, November 2017. Invited Keynote, “Re-assessing the WHI HRT Trials: What Happened? What Can We Believe?”

Cameleo CME and the Royal College of Obstetricians and Gynecologists of Canada, Professional Development Conference, Mykonos, Greece, May 2018, 5 lectures. "Unintended Consequences: Breast Cancer and Diabetes in the Context of CVD Prevention"; "Are We Forgetting Something? HRT, Cognitive Function and Dementia"; "Calcium and Vitamin D: Prevention or Harm?"; "The Silent Epidemic: Prevention of Osteoporosis in the Postmenopausal Woman"; "Re-assessing the WHI HRT Trials: What Happened? What Can We Believe?"

16th Congress of the International Menopause Society, Vancouver, Canada, June 2018, 2 lectures. "A Lesson In Contrasts. What Can We Learn from the Discrepant Breast Cancer Findings in the WHI?"; "The WHI in Perspective"

FORENSIC SCIENTIFIC EXPERT ENGAGEMENTS:

Product liability: Hormone Replacement Therapy (including Multi-District Litigation)

Product liability: Hormonal Contraception

Product liability: Bisphosphonates

Product liability: Retinoids

Product liability: Environmental Toxic Exposure

Pharmaceutical Intellectual Property

Insurance for product liability

Medical malpractice: cardiovascular event associated with medication use

Medical malpractice: failure to diagnose lung cancer, estimated survival

Medical malpractice: complications of peripheral arterial disease, estimated survival

Medical malpractice: Statistical methods related to breast cancer progression

Wrongful death: Life Expectancy (multiple cases in different jurisdictions)

PUBLICATIONS IN PEER-REVIEWED SCIENTIFIC JOURNALS:

Langer, RD TALMRS: Time-affinity linked medical record system. Proceedings of The Eleventh Annual Symposium on Computer Applications in Medical Care. The Computer Society Press, Los Angeles, California, 1987, pp 271-274. Pavlinac D, Langer R, Lenhard L, Deftos L, Magnesium in affective disorders. *Biological Psychiatry*, 1979;14(4),657-661.

Langer, RD: A flexible triage system for use in the home, workplace, and health care institutions. Proceedings, American Association for Medical Sciences and Informatics Congress 1988, American Association for Medical Sciences and Informatics, Washington, DC, 1988, 26-30.

Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. *BMJ*. 1989 May 20;298(6684):1356-7.

Criqui MH, Langer RD, Reed DM. Dietary alcohol, calcium, and potassium. Independent and combined effects on blood pressure. *Circulation*. 1989 Sep;80(3):609-14.

Sallis JF, Criqui MH, Kashani IA, Rupp JW, Calfas KJ, Langer RD, Nader PR, Ross J Jr. A program for health behavior change in a preventive cardiology center. *Am J Prev Med*. 1990;6(2 Suppl):43-50.

Langer RD & Barrett-Connor E: Menopausal estrogen and cardiovascular disease: Is there a relationship? *Obstetrics/Gynecology Report*, 1990;2:255-65.

Langer RD & Barrett-Connor E: Coronary heart disease prevention in women. *Practical Cardiology*, 1991;17(3):45-62.

Langer RD, Ganiats TG, Barrett-Connor E. Factors associated with paradoxical survival at higher blood pressures in the very old. *Am J Epidemiol*. 1991 Jul 1;134(1):29-38. Erratum in: *Am J Epidemiol* 1993 Nov 1;138(9):774.

Kashani IA, Langer RD, Criqui MH, Nader PR, Rupp J, Sallis JF, Houghton R. Effects of parental behavior modification on children's cardiovascular risks. *Ann N Y Acad Sci*. 1991;623:447-9.

Langer RD & Barrett-Connor E: Cardiovascular disease in women. *Contemp Int Med*, 1991;3(6):50-64.

Langer RD, Wark R, Schneiderman LJ, Kaplan RM, Anderson JP, Chen M. A research-oriented medical cost accounting system. *Int J Biomed Comput.* 1991 Jul-Aug;28(3):161-7.

Barrett-Connor E & Langer RD: Cardiovascular events, estrogens, and the menopause. In Morley JE & Korenman SG: *Problems in Geriatric Endocrinology*, Blackwell Scientific Publications, Boston, 1992, pp 336-49.

Kashani IA, Kaplan RM, Criqui MH, Nader PR, Rupp J, Sallis JF, Dimsdale J, Langer RD, Bracker M, Ries AL: Cardiovascular risk factor assessment of medical students as an educational tool. *Am J Prev Med*, 1992;8(6):384-388.

Langer RD, Criqui MH, Reed DM: Lipoproteins and Blood Pressure as Biological Pathways for Effect of Moderate Alcohol Consumption on Coronary Heart Disease. *Circulation*, 1992; 85:910-915.

Criqui MH, Langer RD, Fronck A, Feigelson HS, Klauber MR: Large Vessel and Isolated SVD (chapter), In: *Epidemiology of Peripheral Vessel Disease*. Fowkes FGR (Ed), Springer-Verlag, Ireland, 1991, 85-96.

Criqui MH, Langer RD, Fronck A, Feigelson HS. Coronary disease and stroke in patients with large vessel peripheral arterial disease. *Drugs* 1991;42(suppl5):16-21.

Criqui MH, Langer RD, Fronck A, Feigelson HS, Klauber MR, Ganiats TG, Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med*, 1992; 326:381-6.

Schneiderman LJ, Kronick R, Kaplan RM, Anderson JP, Langer RD. Effects of offering advance directives on medical treatments and costs: A prospective study. *Ann Int Med*, 1992; 117:599-606

Kashani IA, Kaplan RM, Rupp JW, Langer RD, McCann TJ, Sallis JF, Bracker M, Nader P, Dimsdale J, Browner D, Holiday CA, Criqui MH. Effects of a Preventive Cardiology Curriculum on Behavioral Cardiovascular Risk Factors and Knowledge of Medical Students. *Patient Educ & Counseling* 1993, 21:15-27.

Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganiats TG. Blood pressure change and survival after age 75. *Hypertension*, 1993; 22: 551-9

Langer RD & Criqui MH. Stroke and peripheral vascular diseases in women. In: Douglas PS, Ed., Cardiovascular Health and Disease in Women. WB Saunders, Philadelphia, 1993, pp 137-149.

Criqui MH, Denenberg J, Langer RD, Fronck A, Bensussen G. Peripheral arterial disease in hypertension. In Taubert KA, Ed., Hypertension Primer, American Heart Association, Dallas, 1993, pp. 184-87.

Langer RD, Criqui MH, Klauber MR, Barrett-Connor E. Death at low diastolic pressure in the very old: a perfusion effect? *Gerontologist*, 1993;33(Suppl):236.

Nardo CJ, Criqui MH, Langer RD, Coughlin SS. Serum creatinine predicts all-cause and cardiovascular mortality. *Circulation*, 1994;90(4).

Langer RD, Barrett-Connor E. Age and Sex Differences in Coronary Heart Disease Risk Factors. *Am J Epidemiol*, June 1994,139(suppl).

Feigelson, HS, Criqui, MH, Fronck A, Langer, RD, Molgaard, C. Diagnosis of peripheral arterial disease: the sensitivity, specificity and predictive value of non-invasive tests in a defined population. *Am J Epidemiol*, 1994; 140:518-25

Langer RD, Barrett-Connor E. Extended hormone replacement: who should get it, and for how long? *Geriatrics* 1994, 49:20-4; 29.

Schneiderman LJ, Kronick R, Kaplan RM, Anderson JP, Langer RD. Attitudes of seriously ill patients toward treatment that involves high costs and burdens on others. *J Cl Ethics*, Summer 1994; 5:109-12.

Langer RD, Klauber MR, Criqui MH, Barrett-Connor EL. Exercise and Survival in the Very Old. *Am J Ger Cardiol*, 1994, 3:24-34.

Schneiderman LJ, Teetzel H, Kronick R, Anderson JP, Langer RD, Rosenberg E, Kaplan RM. Advance directives, apples and oranges. *Arch Intern Med*. 1995 Jan 23;155(2):217-8.

Greendale GA, Hogan P, Kritz-Silverstein D, Langer RD, Johnson S, Bush, T. Age at menopause in women participating in the Postmenopausal Estrogen/Progestins Interventions (PEPI) Trial: an example of bias introduced by selection criteria. *Menopause*, 1995, 2:27-34

The Postmenopausal Estrogen/Progestin Intervention's (PEPI) Trial Investigators.* Baseline Characteristics of Women in the Postmenopausal Estrogen/Progestin Intervention's Trial. *Control Clin Trials*, 1995, 54S-65S. *(Writing group: Miller VT, Espeland MA, Langer RD, Marcus RM, Stern MD, Shumaker S).

The Writing Group for the PEPI Trial. Effects of estrogen on estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA*, 1995;273:199-208.

Criqui MH, Langer RD, Denenberg JO, Scheidt-Nare C, Barrett-Connor E, Klauber MR. Triglycerides and coronary heart disease death in the elderly. *Circulation*, 1995;91:923.

Langer RD. Women and Heart Disease. *Healthline*, 1995, 14:6-7.

Langer RD. The Epidemiology of Hypertension Control in Populations: Proceedings of the World Hypertension League Inter-American Society of Hypertension Symposium. *Clinical and Experimental Hypertension*, 1995;17(7):1127-44.

Qizilbash N, Lewington S, Duffy S, Peto R, and others. Cholesterol, diastolic blood pressure and stroke - 13000 strokes in 450000 people in 45 prospective cohorts. *Lancet*. 1995;346(N8991):1647-1653.

Bird CE, Criqui MH, Fronck A, Denenberg JO, Klauber MR, Langer RD. The Natural History of Peripheral Arterial Disease: Quantitative Progression by Non-invasive Testing. *Circulation*, 1995;92(8 Suppl):I152

Langer RD, Barrett-Connor E, Criqui MH. Does Coronary Heart Disease Comorbidity Explain the Paradoxical Relation Between Blood Pressure and Survival in the Very Old? *Circulation*, 1995;92(8 Suppl):I218

Langer RD, Criqui MH, Feigelson HS, McCann TJ, Hamburger RN. IgE predicts future non-fatal myocardial infarction in men. *J Clin Epi*, 1996;49(2):203-9.

Criqui MH, Denenberg JO, Bird CE, Fronck A, Klauber MR, Langer RD. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. *J Vascular Med Bio*, 1996;1(1).

Langer RD, Kaplan RM. The paradoxical effects of CHD risk factors in the oldest old. *J Prev & Intervention in the Community*, 1996;13:19-32. Simultaneously published in *Preventing Illness Among People with Coronary Heart Disease*. Ed: JD Piette, RM Kaplan, JR Ferrari. The Haworth Press, Inc., 1996, pp 19-32.

McCann TJ, Criqui MH, Kashani IA, Sallis JF, Calfas KJ, Langer RD, Rupp JW. A randomized trial of cardiovascular risk factor reduction: patterns of attrition after randomization and during follow-up. *J Cardiovasc Risk*. 1997 Feb;4(1):41-6.

Matthews KA, Shumaker SA, Bowen DJ, Langer RD, Hunt JR, Kaplan RM, Klesges RC, Ritenbaugh C. Women's Health Initiative, Why Now?, What Is It? What's New? *Am Psychol*, 1997;52 (2):101-16.

Ross C, Langer RD, Barrett-Connor E. Given diabetes: Is fat better than thin? *Diabetes Care*, 1997; 20(4):650-2.

Langer RD. High stakes in everyday choices: preventive medicine for women. *Am Fam Physician*. 1997 Mar;55(4):1039, 1042, 1047-8.

Langer RD. The puzzle of low diastolic blood pressure and poor survival at advanced ages. *Spectrum International*; 1997.

Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor EL. Cardiovascular Disease in Women: A statement for healthcare professionals from the American Heart Association, *Circulation* 1997;96 (N7):2468-82.

Langer RD, Criqui MH, Barrett-Connor EL, Denenberg JO, Fronck A. Estrogen is associated with greater arterial flow velocities in older women. *Can J Cardiol*, 1997,13(B Suppl):330B

Langer RD. Hazards of a treatment-associated decline in diastolic blood pressure in men aged 80+ with low initial DBP in the Systolic Hypertension in the Elderly Program (SHEP). *Can J Cardiol*. 1997,13(B Suppl):52B

Criqui MH, Denenberg JO, Langer RD, Fronck A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. *Vasc Med*. 1997;2(3):221-6.

Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabala JF, Barnabei VM, Merino MJ, Scully RE. Transvaginal Ultrasonography Compared with Endometrial Biopsy for the Detection of Endometrial Disease. *N Engl J Med*, 1997; 337(25):1792-8.

Bush RA, Langer RD. The effects of insurance coverage and ethnicity on mammography utilization in a postmenopausal population. *West J Med*. 1998 Apr;168(4):236-40.

Criqui MH, Denenberg JO, Langer RD, Fronck AF, Bensussen G. Peripheral arterial disease and hypertension, pgs. 215-7. In *Hypertension Primer, Second Edition*, JL Izzo and HR Black (eds.), American Heart Association 1998.

Langer RD, Estrogen plus progestin was not effective for secondary prevention of coronary heart disease in postmenopausal women. *ACP Journal Club*, 1998;130(1)

Bird CE, Criqui MH, Fronck A, Denenberg JO, Klauber MR, Langer RD. Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing. *Vascular Med* 1999;4:15-21.

Langer RD. Micronized progesterone: a new therapeutic option. *Int J Fertil Womens Med*. 1999 Mar-Apr;44(2):67-73.

Langer, RD. Hormone replacement therapy and coronary heart disease in light of the PEPI Trial. *Int J Fertil*, 1999;44:136-41.

Jean-Louis G, Kripke DF, Assmus JD, Langer RD. Sleep-wake patterns among postmenopausal women: a 24-hour unattended polysomnographic study. *J Gerontol A Biol Sci Med Sci*. 2000 Mar;55(3):M120-3.

Jean-Louis G, Kripke DF, Ancoli-Israel S, Klauber MR, Sepulveda RS, Mowen MA, Assmus JD, Langer RD. Circadian sleep, illumination, and activity patterns in women: influences of aging and time reference. *Physiol Behav*. 2000 Jan;68(3):347-52.

Langer, RD. Progestins: Pharmacologic Characteristics and Clinically Relevant Differences. *Int J Fertil*, 2000;45(Suppl 1):63-72.

Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer RD, Lasser N. Hypertension and its treatment in post-menopausal women: Baseline data from the Women's Health Initiative, *Hypertension* 2000 Nov, 36(5):780-9.

Adhikari A, Criqui MH, Wooll V, Denenberg JO, Fronck A, Langer RD, Klauber M. The epidemiology of chronic venous diseases. *Phlebology*, 2000;15:2-18.

Langer RD, Criqui MH, Denenberg J, Fronck A. The prevalence of venous disease by gender and ethnicity in a balanced sample of four ethnic groups in Southern California. *Phlebology* 2000;15:99-105

Calfas KJ, Criqui MH, Sallis JF, Langer RD, Rupp JW, Kashani IA, McCann TJ. Six-Month Patient Outcomes in a Preventive Cardiology Center. *Prev Cardiol* 2001;4:16-22,27

Lindblad U, Langer RD, Wingard DL, Thomas RG, Barrett-Connor EL. Metabolic syndrome and ischemic heart disease in elderly men and women. *Am J Epidemiol* 2001;153:481-9.

Fronck A, Criqui MH, Denenberg J, Langer Rd. Common femoral vein dimensions and hemodynamics including Valsalva as a function of sex, age, and ethnicity in a population study. *J Vasc Surg.* 2001 May; 33(5):1050-6.

Jean-Louis G, Kripke DF, Cole RJ, Assmus JD, Langer RD. Sleep detection with an accelerometer actigraph: comparisons with polysomnography. *Physiol Behav* 2001;72:21-8

Tuunainen A, Langer RD, Klauber MR, Kripke DF. Short version of the CES-D (Burnam screen) for depression in reference to the structured psychiatric interview. *Psychiatry Res* 2001; 261-70.

Tuunainen A, Kripke DF, Elliott JA, Assmus JD, Rex KM, Klauber MR, Langer RD. Depression and endogenous melatonin in postmenopausal women. *J Affect Disord*, 2002 May;69(1-3):149-58.

Langer RD, Knoke JD, Barrett-Connor EL. The stability of electrocardiographic classification pre- and post- glucose challenge. *Am J Epidemiol* 2002, May;69(1-3):149-58

Wallace-Guy GM, Kripke DF, Jean-Louis G, Langer RD, Elliott JA, Tuunainen A. Evening light exposure: implications for sleep and depression. *J Am Geriatr Soc.* 2002 Apr;50(4):738-9.

Langer RD and Criqui MH. Stroke and peripheral vascular diseases in women. In: Douglas PS, Ed., *Cardiovascular Health and Disease in Women*, 2nd Edition, WB Saunders, Philadelphia, 2001

Langer RD. Hormone replacement and the prevention of cardiovascular disease. *Am J Cardiol.* 2002 Jun 20;89(12 Suppl):36E-46E.

Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA.* 2002 Jul 17;288(3):321-33.

Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the Postmenopausal Estrogens Progestins Interventions trial. *Am J Ob Gyn;* 2002, Nov;100:853-63

Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *The Lancet.* 2002, 360 December 14:1903-1913

Writing Group for the Women's Health Initiative Investigators. Risks of postmenopausal hormone replacement. (Letter to the Editor). *JAMA* 2002, Dec 11;288(22):2823-4

Kripke DF, Jean-Louis G, Elliot JA, Klauber MR, Rex KM, Langer RD. Ethnicity, sleep, mood, and illumination. *Chronobiology International.* 2002, 19(5):963-1000

Langer RD. HRT on trial. (Editorial). *Ob.Gyn. News.* Sep 1, 37(17), 2002:8

Langer RD. Legend meets reality: Estrogen plus progestin and coronary heart disease in the Women's Health Initiative. *Menopausal Medicine* 2003;10(4):5-7.

Fronck A, Denenberg JO, Criqui NH, Langer RD. Quantified duplex augmentation in healthy subjects and patients with venous disease: San Diego population study. *J Vasc Surg.* 2003 May; 37(5):1054-8.

von Muhlen D, Langer RD, Barrett-Connor E. Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study). *Am J Cardiol.* 2003 Jun 1;91(11):1311-5.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy

postmenopausal women: the Women's Health Initiative Randomized Trial. *JAMA*. 2003 Jun 25;289(24):3243-53.

Criqui MH, Jamosmos M, Fronck A, Deneberg JO, Langer RD, Bergan J, Golomb BA. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. *Am J Epidemiol*. 2003 Sep 1; 158(5):448-56.

Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. *Ann Epidemiol*. 2003 Oct;13(9 Suppl):S107-21.

Criqui MH, Denenberg JO, Langer RD, Fronck A. Peripheral Arterial Disease and Hypertension in Hypertension Primer, 3rd Edition, Izzo JL, Black HR, eds. Council on High Blood Pressure Research, American Heart Association, Lippincott Williams & Wilkins, Philadelphia, 2003.

Langer RD. Implications of the Women's Health Initiative. *The Female Patient*, 2003, Oct, suppl 1-2.

Langer RD. Results and Implications of the Women's Health Initiative Trial of Estrogen Plus Progestin. *The Female Patient*, 2003, Oct, suppl 2-5.

Misakian AL, Langer RD, Bensenor IM, Cook NR, Manson JE, Buring JE, Rexrode KM. Postmenopausal hormone therapy and migraine headache. *J Womens Health (Larchmt)*. 2003 Dec;12(10):1027-36.

Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, Allison M, Bonds DE, Masaki K, Caralis P, Kotchen JM; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. *Circulation*. 2004 Feb 10;109(5):620-6.

Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 2004 Apr 14;291(14):1701-12.

Youngstedt, S.D., A. Leung, D.F. Kripke, and R.D. Langer (2004). Association of morning illumination and window covering with mood and sleep in post-menopausal women. *Sleep and Biological Rhythms*, 2, 174-183.

Kripke DF, Jean-Louis G, Elliott JA, Klauber MR, Rex KM, Tuunainen A, Langer RD. Ethnicity, sleep, mood, and illumination in postmenopausal women. *BMC Psychiatry* 2004, 4:8 (07 Apr 2004)

Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, Oberman a, Kotchen JM, Ridker PM. Tissue plasminogen activator and D-dimer as makers for atherothrombotic risk among healthy postmenopausal women. *Circulation*. 2004 Jul 20;110(3):292-300. Epub 2004 Jul 06.

Waters DD, Chair; Gordon D, Rossouw, JE, Cannon RO, Collins P, Herrington DM; Hsia J, Langer RD, Mosca L, Ouyang P, Sopko, G, Stefanick ML. Women's Ischemic Syndrome Evaluation: Current Status and Future Directions, *Circulation*. 2004;109:e53-e55.

Coker LH, Espeland MA, Gu L, Masaki KH, Rapp SR, Langer RD, Stefanick ML, Ockene J, Shumaker SA. Association between reported alcohol intake and changes in cognition: results from the Women's Health Initiative Memory Study (WHIMS). *The Gerontologist* 2004;44(Special Issue 1):82-83.

Yoon IY, Kripke DF, Elliott JA, Langer RD. Naps and circadian rhythms in postmenopausal women. *J Gerontol A Biol Sci Med Sci*. 2004 Aug;59(8):844-8.

Howard B, Kuller L, Langer R, Manson J, Allen C, Assaf A, Cochrane B, Larson J, Lasser N, Rainford M, Van Horn L, Stefanick M, Trevisan M. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the WHI OS. *Circulation*. 2005;111:1462-1470

Espeland MA, Gu L, Masaki KH, Langer RD, Coker LH, Stefanick ML, Ockene J, Rapp SR. Association between reported alcohol intake and cognition: results from the Women's Health Initiative Memory Study. *Am J Epidemiol*. 2005 Feb 1;161(3):228-38.

Phillips LD, Langer, RD. Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis. *Fertil Steril*. 2005 Mar;83(3):558-66.

Langer RD. Postmenopausal hormone therapy: What's appropriate today? *AAFP CME Bulletin*, 2005; 4(1): 1-10.

Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM. Baseline Associations between Postmenopausal Hormone Therapy and Inflammatory,

Haemostatic, and Lipid Biomarkers of Coronary Heart Disease in the Women's Health Initiative Observational Study. *Thromb Haemost*, 2005; 93:1108-16.

Langer RD, Ho E, Denenberg JO, Fronck A, Allison M, Criqui MH. Relationships Between Symptoms and Venous Disease: The San Diego Population Study. *Arch Int Med*, 2005; 165: 1420-24.

Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. *Am J Epidemiol*. 2005 Sep 1;162(5):404-14.

Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP, Fronck A. Ethnicity and peripheral arterial disease: the San Diego Population Study. *Circulation*. 2005 Oct 25;112(17):2703-7.

Allison MA, Tiefenbrun J, Langer RD, Wright CM. *Int J Cardiol*. 2005 Aug 3;103(1):98-104. Atherosclerotic calcification and intimal medial thickness of the carotid arteries.

Allison MA, Cheung P, Criqui MH, Langer RD, Wright CM. Mitral and Aortic Annular Calcification Are Highly Associated With Systemic Calcified Atherosclerosis. *Circulation*, 2006 Feb 6; [Epub ahead of print].

Women's Health Initiative Investigators. Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*, 2006;295(6): 629-42.

Women's Health Initiative Investigators. Low-Fat Dietary Pattern and Risk of Colorectal Cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*, 2006;295(6): 643-54.

Women's Health Initiative Investigators. Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*, 2006;295(6): 655-66.

Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R. Conjugated equine estrogens and coronary disease. *Arch Int Med*, 2006;166:357-65.

Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med*. 2006 Feb 16;354(7):684-96.

Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med*. 2006 Feb 16;354(7):669-83.

Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J. Combined Analysis of Women's Health Initiative Observational and Clinical Trial Data on Postmenopausal Hormone Treatment and Cardiovascular Disease. *Am J Epidemiol*. 2006, 163(7):589-99.

Langer RD, Wood GC, Thomas C. Better Treatment Rates for Undiagnosed Hypertension in Older Patients: A Possible Effect of Comorbidity: The Geisinger Clinic Population (abstract). Presented at the 46th Annual Conference on CVD Epidemiology and Prevention. Phoenix, AZ, Mar 2, 2006.

Langer RD, Wood GC, Thomas C. Markedly negative within individual DBP slope in men aged 75 and older (abstract). The Geisinger Clinic Population. Presented at the 46th Annual Conference on CVD Epidemiology and Prevention. Phoenix, AZ, Mar 2, 2006.

Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. *Arch Int Med*, 2006;166:772-780.

Grandner MA, Kripke DF, Langer RD. Light exposure is related to social and emotional functioning and to quality of life in older women. *Psychiatry Res*. 2006 Jun 30;143(1):35-42. Epub 2006 May 24.

Langer RD, Landgren BN, Rymer J, Helmond FA. Effects of Tibolone and Continuous Combined Conjugated Equine Estrogen/Medroxyprogesterone Acetate on the Endometrium and Vaginal Bleeding: Results of the OPAL Study. *Am J Obstet Gynecol*, 2006; Available online 26 July 2006.

Allison M, Garland C, Chlebowski R, Cricqui M, Langer R, Wu L, Roy H, McTiernan A, Kuller L. The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women. *Am J Epidemiol*. 2006 Jul 17; [Epub ahead of print]

Lobo RA, Creasman WT, Frankel NR, Goodman NE, Hall JE, Ivey SL, Kingsberg S, Langer R, Lehman R, MacArthur DB, Montgomery-Rice V, Notelovitz M, Packin GS, Rebar RW, Rousseau M, Schenken RS, Schneider DL, Sheriff K, Wysocki S. Should Symptomatic Menopausal Women Be Offered Hormone Therapy? *Medscape General Medicine*, 2006;8(2), posted 08/17/06.

Langer RD, Friedman AJ. Effects of E2 and E2/norgestimate hormone therapy on elevated baseline lipids. *J Reprod Med*. 2006 Aug;51(8):610-6.

Hsia J, Manson JE, Kuller L, Pettinger M, Choe JH, Langer RD, et al. Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: Secondary analysis of a randomized trial. *PLoS Clin Trials*, 2006; 1(5):e26.DOI:10.1371/journal.pctr.0010026

Langer, RD, Helmond FA, Yaffe MJ, Stathopoulos VM, Pathiraja K, Gunasekara A. Tibolone Does Not Increase Mammographic Density over a 3-Year Period: OPAL Study (abstract). *Menopause*, 2006;13(6):1005.

Cricqui MH, Denenberg JO, Langer RD, Kaplan RM, Fronck A. Epidemiology of chronic peripheral venous disease. In: JJ Bergan ed. *The Vein Book*. 1st edition. San Diego, CA: Elsevier, 2007:27-37.

Allison MA, DiTomasso D, Cricqui MH, Langer RD, Wright CM. Renal artery calcium: relationship to systemic calcified atherosclerosis. *Vasc Med* 2006; 11; 232.

Langer RD. Progesterone and progestins in postmenopausal hormone therapy. *J Fam Pract*, 2007; Feb(56,suppl):14-21.

Klein R, Deng Y, Klein BE, Hyman L, Seddon J, Frank RN, Wallace RB, Hendrix SL, Kuppermann BD, Langer RD, Kuller L, Brunner R, Johnson KC, Thomas AM, Haan M. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. *Am J Ophthalmol*. 2007 Mar;143(3):473-83. Epub 2007 Jan 10.

Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, Criqui MH. Ethnic-specific prevalence of peripheral arterial disease in the United States. *Am J Prev Med.* 2007 Apr;32(4):328-33.

Criqui MH, Denenberg JO, Bergan J, Langer RD, Fronck A. Risk factors for chronic venous disease: The San Diego Population Study. *J Vasc Surg.* 2007 Jun 26; [Epub ahead of print]

Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, et al; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. *N Engl J Med.* 2007 Jun 21;356(25):2591-602.

Langer RD. The more things change, CHD and the Womens Health Initiative. *Sexuality Reprod & Menop J,* 2007;5(3):6-10.

Park DH, Kripke DF, Louis GJ, Elliott JA, Klauber MR, Rex KM, Tuunainen A, Langer RD. Self-reported sleep latency in postmenopausal women. *J Korean Med Sci.* 2007 Dec;22(6):1007-14.

Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gillian MA, Walsh BW, Chen C, McTiernan A. Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy. *Arch Intern Med.* 2008;168(4):370-377.

Bray PF, Larson JC, LaCroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL; Women's Health Initiative Investigators. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. *Am J Cardiol.* 2008, Jun 1;101(11):1599-1605. Epub 2008 Apr 2.

Allison MA, Manson JE, Langer RD, Carr JJ, Rossouw JE, Pettinger MB, Phillips L, Cochrane BB, Eaton CB, Greenland P, Hendrix S, Hsia J, Hunt JR, Jackson RD, Johnson KC, Kuller LH, Robinson J; for the Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. *Menopause.* 2008 May 2. [Epub ahead of print]

Lamond AJ, Depp CA, Allison M, Langer R, Reichstadt J, Moore DJ, Golshan S, Ganiats TG, Jeste DV. Measurement and predictors of resilience among community-dwelling older women. *J Psychiatr Res.* 2008 Apr 30.

Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. *Am J Epidemiol*. 2008 Jun 15;167(12):1407-15. Epub 2008 Apr 29.

Thomas C, Wood GC, Langer RD, Stewart WF. Elevated blood pressure in primary care varies in relation to circadian and seasonal changes. *J Hum Hypertens*. 2008 Jun 5. [Epub ahead of print]

Langer RD. Postmenopausal Estrogen/Progestin Intervention Trial (PEPI). In *Wiley Encyclopedia of Clinical Trials*, D'Agostino R, Sullivan L, Massaro J (eds). Hoboken: John Wiley & Sons, Inc., 2008.

Allison MA, Manson JE, Langer RD, Aragaki A, Smoller S, Lewis CE, Thomas A, Lawson W, Cochrane BB, Hsia J, Hunt JR, Robinson J. Association Between Different Measures of Blood Pressure and Coronary Artery

Calcium in Postmenopausal Women. *Hypertension*. 2008 Sep 15. [Epub ahead of print]

Song Y, You NC, Hsu YH, Howard BV, Langer RD, Manson JE, Nathan L, Niu T, F Tinker L, Liu S. FTO Polymorphisms Are Associated With Obesity but Not Diabetes Risk in Postmenopausal Women. *Obesity (Silver Spring)*. 2008 Sep 11. [Epub ahead of print]

Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. *JAMA*. 2008 Jul 9;300(2):197-208.

Go AS, Magid DJ, Wells B, Sung SH, Cassidy-Bushrow AE, Greenlee RT, Langer RD, et al. The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research. *Circ Cardiovasc Qual Outcomes*. 2008 Nov 1;1(2):138-147.

Holmes JH, Brown J, Hennessy S, Lane K, Langer RD, Lazarus R, O'Connor PJ, Strom BL, Platt R. Developing a distributed research network to conduct population-based studies and safety surveillance. *AMIA Annu Symp Proc.*, 2008;Nov 6:973.

Millen AE, Pettinger M, Freudenheim JL, Langer RD, Rosenberg CA, Mossavar-Rahmani Y, Duffy CM, Lane DS, McTiernan A, Kuller LH, Lopez AM, Wactawski-Wende J. Incident invasive

breast cancer, geographic location of residence, and reported average time spent outside. *Cancer Epidemiol Biomarkers Prev.* 2009 Feb;18(2):495-507. Epub 2009 Feb 3.

Langer RD. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. *Am J Epidemiol.* 2009 Mar 15;169(6):784-5; author reply 785-6. Epub 2009 Feb 10.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. *Am J Epidemiol.* 2009 Jul 1;170(1):12-23. Epub 2009 May 25.

Langer RD. Efficacy, Safety, and Tolerability of Low-dose Hormone Therapy in Managing Menopausal Symptoms. *J Am Board Fam Med.* 2009 Sep-Oct;22(5):563-73..

Berger JS, Brown DL, Burke GL, Oberman A, Kostis JB, Langer RD, Wong ND, Wassertheil-Smoller S. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease, the Women's Health Initiative Observational Study. *Circ Outcomes:2009;2:78-87.*

Grandner MA, Kripke DF, Naidoo N, Langer RD. Relationships among dietary nutrients and subjective sleep, objective sleep, and napping in women. *Sleep Med*, 2010; [Epub ahead of print]PMID: 20005774.

Langer RD. New-onset breast tenderness is not a useful predictor of breast cancer. *International Menopause Society - Menopause Live*, published online Nov 30, 2009.

Chlebowski RT, Anderson G, Manson J, Pettinger M, Yasmeeen S, Lane D, Langer RD, et al. Estrogen Alone and Breast Cancer Detection by Mammography and Breast Biopsy. *J Clin Oncol*, 2010 Jun 1;28(16):2690-7. Epub 2010 May 3..

Langer RD. On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause. *Climacteric.* 2010 Aug;13(4):303-6.

Manson JE, Allison MA, Carr JJ, Langer RD, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. *Menopause.* 2010 Jul;17(4):683-91.

Allison MA, Manson JE, Aragaki A, Langer RD, et al. Vasomotor symptoms and coronary artery calcium in postmenopausal women. *Menopause*, 2010 Nov-Dec;17(6):1136-45.

Kripke DF, Langer RD, Elliott JA, Klauber MR, Rex KA. Mortality related to actigraphic long and short sleep. *Sleep Med*, .*Sleep Med*. 2011 Jan;12(1):28-33.

Takata Y, Kristal AR, King IB, Song X, Diamond AM, Foster CB, Hutter CM, Hsu L, Duggan DJ, Langer RD, et al., Serum Selenium, Genetic Variation in Selenoenzymes, and Risk of Colorectal Cancer: Primary Analysis from the Women's Health Initiative Observational Study and Meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2011, Sep;20(9):1822-30. Epub 2011 Jul 15.

Kripke DF, Langer RD, Kline LE. Hypnotics association with mortality or cancer: a matched cohort study. *BMJ Open*, *BMJ Open*. 2012 Feb 27;2(1):e000850. **[Correspondence from the Editor of the BMJ Open received February 16, 2016: “your article is the most cited article in the journal's history”]**

Langer RD, Manson JE, Allison MA. Have We Come Full Circle – Or Moved Forward? The Women's Health Initiative 10 Years On. *Climacteric*, 2012 Jun;15(3):206-12.

Kripke DF, Langer RD, Kline LE. Do no harm: not even to some degree. *J Clin Sleep Med*, 2012, Aug 15;8(4):353-4. doi: 10.5664/jcsm.2018.

de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, Davis SR, Gompel AA, Henderson VW, Langer R, Lobo RA, Plu-Bureau G, Sturdee DW; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. *Climacteric*. 2013 Jun;16(3):316-37.

Kulick D, Langer RD, Ashley JM, Gans KM, Schlauch K, Feller C. Live well: a practical and effective low-intensity dietary counseling intervention for use in primary care patients with dyslipidemia--a randomized controlled pilot trial. *BMC Fam Pract*. 2013 May 12;14:59. doi: 10.1186/1471-2296-14-59.

Kerr J, Norman G, Millstein R, Adams MA, Morgan C, Langer RD, Allison M. Neighborhood Environment and Physical Activity Among Older Women: Findings From the San Diego Cohort of the Women's Health Initiative. *J Phys Act Health*. 2013 Aug 19. [Epub ahead of print] PMID: 23963780.

Fowkes F, Murray G, Butcher I, Folsom A, Hirsch A, Couper D, Debacker G, Kornitzer M, Newman A, Sutton-Tyrrell K, Cushman M, Lee A, Price J, D'Agostino R Sr, Murabito J, Norman P, Masaki K, Bouter L, Heine R, Stehouwer C, McDermott M, Stoffers H, Knottnerus J, Ogren M, Hedblad B, Koenig W, Meisinger C, Cauley J, Franco O, Hunink M, Hofman A, Witteman J, Criqui M, Langer R, Hiatt W, Hamman R; Ankle Brachial Index Collaboration. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. *Eur J Prev Cardiol.* 2013 Dec 23. [Epub ahead of print] PMID: 24367001

Kripke DF, Langer RD. Evidence for harm, comment on 'Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study'. *Br J Clin Pharm.* 2014; 78(1), 188-189. DOI:10.1111/bcp.12265

Pines A, Langer RD. The cardiovascular safety aspects of calcium supplementations: where does the truth lie? A personal perspective. *Climacteric.* 2014 Oct 16:1-5. [Epub ahead of print] PMID: 25318377

Daka B, Langer RD, Larsson CA, Rosén T, Jansson PA, Råstam L, Lindblad U. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. *BMC Endocr Disord.* 2015 Jul 25;15:35. PMID: 26209521

Baber RJ, Panay N, Fenton A. The IMS Writing Group including Langer RD. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric.* 2016 Apr;19(2):109-150. Epub 2016 Feb 12. PMID: 26872610

Langer RD. The evidence base for HRT - what can we believe? *Climacteric.* 2017 Apr;20(2):91-96. doi: 10.1080/13697137.2017. PMID:28281363

Langer RD, Simon JA, Pines A, Lobo RA, Hodis HN, Pickar JH, Archer DF, Sarrel PM, Utian WH. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. *Climacteric.* 2017 Oct;20(5):402-413. doi: 10.1080/13697137.2017.1362156. Epub 2017 Aug 14. PMID: 28805475

Langer RD, Simon JA, Pines A, Lobo RA, Hodis HN, Pickar JH, Archer DF, Sarrel PM, Utian WH. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. *Menopause.* 2017 Oct;24(10):1101-1112. doi: 10.1097. PMID: 28872490

Poornima IG and the WHI CAC Study Investigators. Coronary Artery Calcification (CAC) and Post-Trial Cardiovascular Events and Mortality Within the Women's Health Initiative (WHI) Estrogen-Along Trial. *J Am Heart Assoc.* 2017 Oct 27;6(11). pii: e006887. doi: 10.1161/JAHA.117.006887.